AbBaltis

Executive Summary

AbBaltis is a UK-based biotech company founded in 2018 that specializes in supplying disease state plasma, serum, and residual clinical samples to the In Vitro Diagnostics (IVD) and broader biotech markets. By providing these critical biological materials along with plasma processing and bespoke research services, AbBaltis accelerates diagnostic test development for its clients. The company serves as a vital link in the diagnostic development supply chain, enabling researchers to access high-quality, clinically relevant samples without the complexities of sourcing from multiple providers. Its location in Cambridge, a global biotech hub, positions it well to collaborate with leading diagnostic companies and research institutions. AbBaltis operates as a private company with no disclosed funding or valuation, indicating a bootstrap or early-stage profile. Its focus on a niche but essential service—sample procurement and processing—allows it to support the growing demand for accurate and rapid diagnostic tests. As the diagnostic market expands, driven by trends in personalized medicine and point-of-care testing, AbBaltis stands to benefit from increased outsourcing of sample sourcing. The company's ability to maintain sample quality and regulatory compliance will be key to its growth. With no public catalysts on record, future developments may include expanding its sample catalog, forming strategic partnerships, or seeking external funding to scale operations.

Upcoming Catalysts (preview)

• Q4 2026Major contract with a top-10 diagnostic company30% success
• Q2 2027Expansion of sample catalog to include rare disease cohorts45% success
• Q1 2027Series A funding round announced20% success